• Global follicular lymphoma drugs market size was valued at USD 1.8 billion in 2024. The market is projected to grow from USD 1.94 billion in 2025 to USD 3.05 billion by 2032, exhibiting a CAGR of 8.0% during the forecast period.
Email:
• Follicular lymphoma is a slow-growing type of non-Hodgkin's lymphoma that affects white blood cells called lymphocytes.
Drugs for follicular lymphoma primarily include Anti-CD20 monoclonal antibodies (such as rituximab), chemotherapy agents, kinase inhibitors, and other targeted therapies. The market is currently dominated by three key players Roche, Teva, andBayerwhichcollectivelyholdabout57%marketshare.
Email:
By Types
•Anti-CD20 monoclonal antibodies (mAbs)
•Subtypes: Rituximab, Obinutuzumab, Ofatumumab
•Chemotherapy agents
•Subtypes: Bendamustine, Cyclophosphamide, Doxorubicin
•Kinase inhibitors
•PI3K inhibitors
